We survey the Therapeutic Goods Administration’s active enforcement of the therapeutic goods advertising framework during the COVID-19 pandemic and provide guidance on complying with the framework.
Read on for an update on the progress of the Royal Commission into Aged Care Quality and Safety, including the final submissions and recommendations by Counsel Assisting.
Find out more about the Full Federal Court’s decision in Mylan v Sun Pharma, which clarifies the law on the construction, infringement and novelty of “Swiss-style” patent claims in Australia.
We discuss the recent payroll tax decision by the Victorian Court of Appeal, Optical Superstores, and consider the potential implications on commercial arrangements in healthcare or allied health.
We review the competition law issues arising in the merger of Mylan and Pfizer’s Upjohn division, in particular the divestments required to obtain approval from the Australian Competition and Consumer Commission.
We consider the Commonwealth’s unsuccessful claim for compensation pursuant to an undertaking as to damages by Sanofi for its clopidogrel (Plavix®) products, and the consequences.
Partner Shaun Temby outlines the issues companies may face when advertising claims are not based on reliable or accurate scientific data.
Partner Aaron Kloczko identifies what you need to know about the National Clinical Trials Governance Framework pilot.